ClinicalTrials.gg
Not yet recruitingNCT07641322Updated Jun 11, 2026

Dentin Hypersensitivity in Orthodontic Patients: Triple-Blinded, Randomized Trial of Three Desensitizing Agents.

An interventional study of TOOTH PASTE(NHA) and TOOTH PASTE (NOVAMIN) in Dentin Desensitizing Agents, sponsored by Nishtar Medical University. Not yet recruiting. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Nishtar Medical University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The effect of desensitizing agents will be studied on dentin hypersensitivity in orthodontic patients.it is a randomized controlled trial. three experimental groups and one placebo group.

02

Conditions studied

  • Dentin Desensitizing Agents
03

In context

Lead sponsor

Nishtar Medical University is the lead sponsor of 29 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Orthodontic patients aged 18-40 years.
  • Presence of mild to moderate dentin (VAS ≥ 4).
  • Willingness to comply with a 12-week follow-up period.
  • No active periodontal disease or untreated caries.
  • Not pregnant or breastfeeding.
  • No history of allergy to desensitizing agents

Exclusion criteria

Exclusion Criteria:

  • o Patients with systemic conditions affecting oral health (e.g., diabetes, ).

    • Patients using medications that affect tooth sensitivity (e.g., anti-inflammatory drugs).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    TEST TOOTHPASTE GROUP 1

    Participants in this arm will use the test toothpaste twice daily for 8 weeks.

    Other: TOOTH PASTE(NHA)

  • Active comparator
    TEST TOOTH PASTE GROUP 2

    Participants in this arm will use the test toothpaste twice daily for 8 weeks.

    Other: TOOTH PASTE (NOVAMIN)

  • Active comparator
    TEST TOOTH PASTE GROUP 3

    Participants in this arm will use the test toothpaste twice daily for 8 weeks.

    Other: TOOTH PASTE (PROARGIN)

  • Placebo comparator
    TEST TOOTH PASTE GROUP 4

    Participants in this arm will use the test toothpaste twice daily for 8 weeks.

    Other: TOOTH PASTE ( NON DESENSITIZING)

Interventions

  • OtherTOOTH PASTE(NHA)

    TOOTH PASTES CONTAINING NHA.

  • OtherTOOTH PASTE (NOVAMIN)

    TOOTH PASTE CONTAINING NOVAMIN

  • OtherTOOTH PASTE (PROARGIN)

    TOOTH PASTE CONTAINING PROARGIN.

  • OtherTOOTH PASTE ( NON DESENSITIZING)

    TOOTH PASTE A NON-DESENSITIZING CONTROL

06

What researchers measure

Primary outcomes

  1. REDUCTION IN DENTIN HYPERSENSITIVITY

    Change in dentin hypersensitivity scores from baseline to 8 weeks using the Visual Analog Scale (VAS) and Schiff Cold Air Sensitivity Scale.

    Time frame: 8 WEEKS

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — IM NOT COMFORTABLE

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07641322
Lead sponsor
Nishtar Medical University
Responsible party
Fatima Khalid (Dr Fatima Khalid, Nishtar Medical University) — Principal investigator
First posted
Jun 11, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Oct 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Jun 11, 2026

Study contacts

FATIMA KHALID, BDS
Contact
fatimakhalid9921@gmail.com
03128287657
Dr. Zubair Hassan Awaisi, FCPS
study chair · PRINCIPAL NID MULTAN

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion